Skip to main content

type 2 diabetes Archives

Immune cells drive beta cell loss in Type 2 diabetes

Sep. 8, 2022—Vanderbilt researchers have discovered details of pancreatic beta cell loss — and potential therapeutic targets — during conditions of overnutrition, as occurs in obesity.

Read more


Diabetes, cardiovascular drug targets

May. 24, 2022—Targeting receptors of the inflammatory lipid signaling molecule PGE2 may offer a new way to tackle both Type 2 diabetes and cardiovascular disease, Vanderbilt researchers have discovered.

Read more


Study sheds light on the dark side of obesity

May. 12, 2022—Vanderbilt research that promotes the anti-inflammatory pathway in macrophages could also reduce some of the bad side effects of obesity.

Read more


Gene network linked to Type 2 diabetes

May. 5, 2022—Vanderbilt researchers used a novel analytical approach to identify a network of genes associated with Type 2 diabetes, including 31 genes that had not previously been associated with the disease.

Read more


New insights into hypothalamic obesity

Feb. 10, 2022—A common Type 2 diabetes treatment being tested for hypothalamic obesity had unexpected results on weight loss and total energy expenditure, Vanderbilt researchers report.

Read more


Impact of digital health interventions

Jan. 31, 2022—Vanderbilt researchers test and recommend statistical approaches to study the association between engagement with digital health interventions and clinical outcomes.

Read more


New way to bEET insulin resistance

Nov. 11, 2021—Signaling molecules called EETs could improve insulin resistance, a primary risk factor for Type 2 diabetes and cardiovascular disease, Vanderbilt researchers have discovered.

Read more


Gene expression in diabetic nephropathy

Aug. 5, 2021—Vanderbilt researchers are looking to mRNA populations in podocytes — kidney cells that help filter blood — to help identify potential targets for treating diabetic kidney disease.

Read more


Study shows continuous glucose monitors improve management of type 2 diabetes

Jul. 15, 2021—For patients with type 2 diabetes treated with basal or long-acting insulin, the use of continuous glucose monitors (CGMs) can result in significantly lower hemoglobin A1C (a blood test that reflects average blood glucose levels over three months), and better management of the disease according to a study recently published in the journal JAMA.

Read more


Type 2 diabetes medication shown to benefit asthma patients

May. 20, 2021—Type 2 diabetes patients who also have asthma are benefitting from a diabetes medication, typically given to help the pancreas produce more insulin, that also improves asthma symptoms and may reduce lung and airway inflammation.

Read more


Gene variant and glucose metabolism

Feb. 18, 2021—Genetic variation that impacts glucose- and insulin-related signaling affects responses to type 2 diabetes treatments and warrants further study.

Read more


A cohort for type 2 diabetes studies

Nov. 17, 2020—A study group of more than 600,000 patients with type 2 diabetes, identified from electronic medical records in the PCORnet national research network, could be valuable for assessing the safety of type 2 diabetes drugs.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more